[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Hua SC, Chen SY, Lu CH, Kao YT, Yu HI, Chen PT, Lee YR, Chang TC: The effects of growth inhibitory peptide on follicular thyroid cancer cell growth, migration, and invasion. Tumori; 2010 May-Jun;96(3):448-51
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although differentiated thyroid cancers are associated with a favorable survival, the prognosis worsens dramatically for patients with distant metastasis.
  • For FTC that is resistant to radioactive iodine, new treatments are urgently needed.
  • Human alpha-fetoprotein (HAFP) is a tumor-associated fetal protein that has been demonstrated to regulate tumorigenesis.
  • In addition, cell migration and invasion assays were used to measure tumor metastasis inhibition effects in vitro.
  • RESULTS: GIP did not inhibit WRO cell proliferation in a time- or dose-dependent manner.
  • GIP may potentially serve as an anti-FTC metastasis agent aiding current chemotherapy regimens.
  • [MeSH-major] Adenocarcinoma, Follicular / drug therapy. Adenocarcinoma, Follicular / pathology. Antineoplastic Agents / pharmacology. Membrane Proteins / pharmacology. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / pathology
  • [MeSH-minor] Cell Movement / drug effects. Cell Survival / drug effects. Humans. Neoplasm Invasiveness. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845807.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Membrane Proteins; 0 / growth inhibitory proteins
  •  go-up   go-down


2. Hueber PA, Waters P, Clark P, Eccles M, Goodyer P: PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int; 2006 Apr;69(7):1139-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal cell carcinoma (RCC) is the most common kidney malignancy and has a poor prognosis owing to its resistance to chemotherapy.
  • RCC cells overexpress the transcription factor, PAX2, normally expressed in fetal kidney but downregulated at birth.
  • Here, we show that PAX2 confers resistance to cisplatin-induced apoptosis in normal kidney cells and fetal kidney explants.
  • Human embryonic kidney 293 cells transfected with a PAX2 expression vector and exposed to cisplatin (40 microM) exhibited 45 +/- 15% as much caspase-3 cleavage compared to control cells.
  • Murine fetal (embryonic day 15) kidney explants from PAX2(1Neu)+/- mice exposed to cisplatin (25 microM x 24 h) had 50% increased apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling staining).
  • We then show that RCC cells (CAKI-1 (human, Caucasian, kidney, carcinoma) and ACHN (human, Caucasian, kidney, adenocarcinoma)) express PAX2 protein.
  • These findings suggest that PAX2 confers resistance to cisplatin-induced apoptosis in non-transformed kidney cells and fetal kidney explants.
  • Conceivably, a therapeutic strategy that inactivates Pax2 in vivo might enhance the efficacy of conventional cytotoxic drugs against RCC.
  • [MeSH-major] Apoptosis / drug effects. Cisplatin / pharmacology. PAX2 Transcription Factor / genetics
  • [MeSH-minor] Adenocarcinoma. Animals. Carcinoma, Renal Cell. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Genetic Vectors. Humans. Kidney Neoplasms. Mice. RNA, Small Interfering / genetics. Recombinant Proteins / antagonists & inhibitors. Transfection

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Kidney Int. 2006 Nov;70(9):1666. Clarke, P [corrected to Clark, P]
  • (PMID = 16609680.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Pax2 protein, mouse; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX: Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol; 2008 Jun 28;14(24):3903-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma.
  • AIM: To explore the method of isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma cell line PANC-1.
  • METHODS: The PANC-1 cells were cultured in Dulbecco modified eagle medium F12 (1:1 volume) (DMEM-F12) supplemented with 20% fetal bovine serum (FBS).
  • Subpopulation cells with properties of tumor stem cells were isolated from pancreatic adenocarcinoma cell line PANC-1 according to the cell surface markers CD44 and CD24 by flow cytometry.
  • And the tumor growth of different subpopulation cells which were injected into the hypodermisof right and left armpit of nude mice was studied, and expression of CD44 and CD24 of the CD44(+)CD24(+) cell-formed nodules and PANC-1 cells were detected by avidin-biotin-peroxidase complex (ABC) immunohistochemical staining.
  • Implantation of 10(4) CD44(-)CD24(-) cells in nude mice showed no evident tumor growth at wk 12.
  • CONCLUSION: CD44 and CD24 may be used as the cell surface markers for isolation of pancreatic cancer stem cells from pancreatic adenocarcinoma cell line PANC-1.
  • Subpopulation cells CD44(+)CD24(+) have properties of tumor stem cells.
  • Because cancer stem cells are thought to be responsible for tumor initiation and its recurrence after an initial response to chemotherapy, it may be a very promising target for new drug development.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Separation / methods. Neoplastic Stem Cells / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Antigens, CD24 / metabolism. Antigens, CD44 / metabolism. Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Humans. Male. Mice. Mice, Nude. Tetrazolium Salts. Thiazoles. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6574-81 [16166435.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):899-904 [16327766.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7341-7 [16849585.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 [17097610.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Natl Vital Stat Rep. 2000 Jul 24;48(11):1-105 [10934859.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 [12511867.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):194-201 [12652646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • (PMID = 18609717.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Antigens, CD44; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue
  • [Other-IDs] NLM/ PMC2721450
  •  go-up   go-down


Advertisement
4. Yu L, Li X, Yang W: Pulmonary blastoma metastatic to the ovary. Int J Gynecol Pathol; 2009 Jan;28(1):59-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary blastoma metastatic to the ovary.
  • Pulmonary blastoma (PB) is a rare and aggressive pulmonary malignancy.
  • A 38-year-old woman was diagnosed as biphasic PB (1 subgroup of sarcomatoid carcinoma) and treated by surgery, radiotherapy, and chemotherapy.
  • The metastatic tumor was composed exclusively of epithelial components resembling well-differentiated fetal adenocarcinoma.
  • [MeSH-major] Lung Neoplasms / pathology. Ovarian Neoplasms / secondary. Pulmonary Blastoma / secondary

  • Genetic Alliance. consumer health - Blastoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Jul;29(4):339-40 [20567146.001]
  • (PMID = 19047906.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Matsuoka T, Sugi K, Matsuda E, Umemori Y, Okabe K, Hirasawa K, Azuma T: [Clear cell adenocarcinoma with acomponent of well-differentiated fetal adenocareinoma; report of a case]. Kyobu Geka; 2006 Aug;59(9):867-70
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell adenocarcinoma with acomponent of well-differentiated fetal adenocareinoma; report of a case].
  • A 69-year-old woman complaining of a cough was admitted to our hospital.
  • Chest X-ray showed a mass in the right lower lung field.
  • Chest computed tomography (CT) showed a tumor with notch, 3 cm in diameter, in the right lower lobe (S9-S10).
  • The tumor was diagnosed as adenocarcinoma by the biopsy under chest CT.
  • The tumor was whitish solid mass, 35 x 34 x 29 mm in size.
  • Histopathologically, the tumor was diagnosed as clear cell adenocarcinoma with a component of well-differentiated fetal adenocarcinoma (WDFA), pT2N0M0, stage IB.
  • The patient was discharged and received postoperative chemotherapy (UFT).
  • The patient has been doing well without any tumor recurrence for 1 year postoperatively.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922450.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE: Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer; 2002 Sep 20;101(3):224-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer therapies based on the inhibition of angiogenesis by endostatin have recently been developed.
  • P125A has a stronger growth-inhibitory effect on endothelial cell proliferation than wild-type endostatin.
  • The VEGF receptors fetal liver kinase-1 (Flk-1) and Fms-like tyrosine kinase-1 (Flt-1) become highly expressed in epithelial tumor and endothelial cells in the mammary carcinomas, suggesting a potential autocrine effect for VEGF on tumor cell growth.
  • Angiopoietin-2 mRNA levels are also increased during tumor progression.
  • CD-31 (platelet-endothelial cell adhesion molecule [PECAM]) staining revealed that blood vessels developed in tumors larger than 1 mm The administration of P125A human endostatin in C3(1)/Tag females resulted in a significant delay in tumor onset, decreased tumor multiplicity and tumor burden and prolonged survival of the animals.
  • Endostatin treatment did not reduce the number of preinvasive lesions, proliferation rates or apoptotic index, compared with controls.
  • However, mRNA levels of a variety of proangiogenic factors (VEGF, VEGF receptors Flk-1 and Flt-1, angiopoietin-2, Tie-1, cadherin-5 and PECAM) were significantly decreased in the endostatin-treated group compared with controls.
  • These results demonstrate that P125A endostatin inhibits the angiogenic switch during mammary gland adenocarcinoma tumor progression in the C3(1)/Tag transgenic model.
  • [MeSH-major] Adenocarcinoma / blood supply. Collagen / therapeutic use. Mammary Neoplasms, Experimental / blood supply. Neovascularization, Pathologic / drug therapy. Peptide Fragments / therapeutic use. Receptor Protein-Tyrosine Kinases / metabolism. Receptors, Growth Factor / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12209972.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA073871
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Endostatins; 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Peptide Fragments; 0 / Receptors, Growth Factor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 63231-63-0 / RNA; 9007-34-5 / Collagen; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


7. Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, Montaldo PG, De Falco G, Caruso A, Vacca A, Ponzoni M: Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer; 2001 Nov 1;94(3):314-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoids are a class of natural or synthetic compounds that participate in the control of cell proliferation, differentiation and fetal development.
  • HPR was also able to significantly repress the spontaneous growth of endothelial cells, requiring at least 48-72 hr of treatment with HPR, followed by a progressive accumulation of cells in G(1) at subsequent time points.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Antineoplastic Agents / pharmacology. Fenretinide / pharmacology. Neovascularization, Pathologic. Neuroblastoma / blood supply. Neuroblastoma / drug therapy
  • [MeSH-minor] Adenocarcinoma / blood supply. Adrenal Glands / blood supply. Animals. Cell Cycle. Cell Division. Cell Line. Cell Movement. Chick Embryo. Chorion. Endometrial Neoplasms / blood supply. Endothelial Growth Factors / metabolism. Endothelium / cytology. Enzyme-Linked Immunosorbent Assay. Female. Fibroblast Growth Factor 2 / metabolism. Flow Cytometry. Humans. Immunohistochemistry. Kinetics. Lymphokines / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Tumor Cells, Cultured. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745408.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; 187EJ7QEXL / Fenretinide
  •  go-up   go-down


8. Oztürk HB, Vural B, Calışkan E, Solakoğlu S: Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc; 2010;11(3):131-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.
  • MATERIAL AND METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research.
  • After trypsinization in 0.5% in calcium magnesium, free phosphate buffer solution (CMFPBS) cells were seeded on glass slides in 24-well plates containing DMEM-F12 medium and 10% fetal calf serum as culture medium.
  • GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells.
  • Apoptosis and cells proliferations were evaluated after 12, 24, 48 and 72(th) hours of incubation.
  • RESULTS: Apoptotic index in grade I EEC cell line among ganirelixoctreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p<0.001, p=0.001).
  • Time dependent antiproliferative effect was obtained with leuprolide and leuprolide-octreotide in grade I EEC (p<0.001, p<0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591918.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939219
  • [Keywords] NOTNLM ; Endometrial cancer / apoptosis / cell proliferation / gonadotropin-releasing hormone analogues / octreotide
  •  go-up   go-down


9. Bini A, Ansaloni L, Grani G, Grazia M, Pagani D, Stella F, Bazzocchi R: Pulmonary blastoma: report of two cases. Surg Today; 2001;31(5):438-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary blastoma: report of two cases.
  • Pulmonary blastomas are a group of rare malignant neoplasms subdivided into three categories: classic biphasic pulmonary blastoma (CBPB), well-differentiated fetal adenocarcinoma (WDFA), and pleuropulmonary blastoma (PPB).
  • Both were heavy smokers and presented with a history of hemoptysis.
  • Physical examination revealed slightly significant findings, chest radiographs showed a large pulmonary mass, confirmed by computed tomography, and bronchoscopic biopsies were not diagnostic.
  • In the first patient, local recurrence with multiple bilateral lung metastases was found 6 months later and despite chemotherapy, he died of respiratory failure 1 year after his operation.
  • We conclude that more aggressive and multidisciplinary treatment should be adopted for CBPB, and because of its low incidence, it is important to unify individual experiences in a central registry to gather as much information as possible regarding the biological and clinical features of this unusual disease.
  • [MeSH-major] Lung Neoplasms / surgery. Pulmonary Blastoma / surgery

  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11381509.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Marnitz S, Schmittel A, Bolbrinker J, Schmidt FP, Fons G, Kalache K, Schneider A, Köhler C: The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum. Fertil Steril; 2009 Nov;92(5):1748.e1-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum.
  • OBJECTIVE: To evaluate the feasibility, toxicity, and pharmacokinetics in the maternal and fetal compartments during chemotherapy in a pregnant patient with cervical cancer.
  • PATIENT: A 35-year-old woman was diagnosed with an adenocarcinoma FIGO stage IB1 of the cervix uteri at 14 weeks' gestation with twin pregnancy.
  • Three cycles of neoadjuvant chemotherapy consisting of cisplatin during the second and third trimester were given and well tolerated.
  • Amniocentesis was performed at the time of the second cisplatin cycle.
  • MAIN OUTCOME MEASURE(S) AND RESULT(S): The concentration in the amniotic fluid samples reached 10% of the maternal blood levels at this time.
  • The twins developed normally and displayed no chemotherapically related side effects.
  • At the time of delivery, the corresponding concentration in the amniotic fluid was approximately one-third of the umbilical cord levels.
  • One-tenth of the maternal serum concentration was detected in the amniotic fluid; the concentration of cisplatin in the umbilical cord was three times higher than in the amniotic fluid.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Cisplatin / therapeutic use. Pregnancy, Multiple. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Amniotic Fluid / chemistry. Amniotic Fluid / metabolism. Antineoplastic Agents / therapeutic use. Feasibility Studies. Female. Fetal Blood / chemistry. Fetal Blood / metabolism. Humans. Laparoscopy. Maternal-Fetal Exchange / drug effects. Mothers. Neoplasm Staging / methods. Osmolar Concentration. Pregnancy. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / pathology. Twins


11. Sun SH, Zheng M, Ding K, Wang S, Sun Y: A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther; 2008 Jun;7(6):845-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy.
  • The efficacy of MI-43 was tested against two pairs of human lung cancer lines differing in p53 status: adenocarcinoma A549 (p53 wild-type, wt) and H522 (p53-null) and non-small cell lung carcinoma H460 (p53wt) and H1299 (p53-null).
  • Importantly, MI-43 is much less toxic to normal fetal lung fibroblast, MRC5 cells.
  • Thus, MI-43 or its analogues could be further developed as a novel class of anticancer drug for lung cancer cells harboring wt p53 as a single agent or in combination with chemo-drugs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Apoptosis. Gene Expression Regulation, Neoplastic. Indoles / pharmacology. Lung Neoplasms / drug therapy. Proto-Oncogene Proteins c-mdm2 / metabolism. Spiro Compounds / pharmacology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Caspase 3 / metabolism. Cell Cycle. Cell Line, Tumor. Drug Synergism. Fibroblasts / metabolism. Humans. Inhibitory Concentration 50. Models, Chemical

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Jun;7(6):853-5 [18535402.001]
  • (PMID = 18340116.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01-CA111554; United States / NCI NIH HHS / CA / P30CA046592
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / MI 43 compound; 0 / Spiro Compounds; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspase 3; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


12. Marnitz S, Köhler C, Oppelt P, Schmittel A, Favero G, Hasenbein K, Schneider A, Markman M: Cisplatin application in pregnancy: first in vivo analysis of 7 patients. Oncology; 2010;79(1-2):72-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Empirical cisplatin is recommended to prevent cancer progression until fetal maturity.
  • Seven patients with cervical cancer in the second trimester decided to delay delivery together with neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Agents / metabolism. Antineoplastic Agents / therapeutic use. Cisplatin / metabolism. Cisplatin / therapeutic use. Neoadjuvant Therapy / methods. Pregnancy Complications, Neoplastic / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Amniotic Fluid / metabolism. Carcinoma, Squamous Cell / drug therapy. Cesarean Section. Chemotherapy, Adjuvant. Female. Fetal Blood / metabolism. Humans. Hysterectomy. Interdisciplinary Communication. Laparoscopy. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Staging. Pregnancy. Pregnancy Trimester, Second. Radiotherapy, Adjuvant


13. Nogales FF, Buriticá C, Regauer S, González T: Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors. Am J Surg Pathol; 2005 Sep;29(9):1247-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors.
  • We present, for the first time, two yolk sac tumors (YST) in women 37 and 18 years of age, one with a typical parietovisceral pattern and the other with a glandular pattern, which were associated with extensive areas of mucinous carcinoid (MC).
  • The tumor in the first case had numerous nodules of tubulopapillary YST that merged with well-differentiated MC.
  • This patient responded well to chemotherapy.
  • The tumor in the second case consisted of an AFP-positive glandular YST, with a glandulopapillary pattern closely resembling fetal lung type adenocarcinoma, coexisting with an AFP-negative, cytokeratin 20-positive, atypical MC; transitional areas between the two components were also seen.
  • We think that, in these cases, MC represented an unusual form of endodermal differentiation of the YST.
  • It is important to differentiate the yolk sac and carcinoid components due to their different responses to chemotherapy and to evaluate the possibility of mucinous carcinoid developing into a highly aggressive carcinoma.
  • [MeSH-major] Carcinoid Tumor / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Immunohistochemistry. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096416.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Boyd A, Cowie V, Gourley C: The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature. Int J Gynecol Cancer; 2009 Feb;19(2):273-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature.
  • For early-stage disease arising in late second/third trimester, treatment may be delayed until delivery.
  • CASE: A 26-year-old woman presented at 21 weeks gestation with a stage IIB high-grade clear cell cervical carcinoma.
  • Fifteen months post treatment, both patient and baby remain well.
  • CONCLUSION: Neoadjuvant cisplatin chemotherapy can be used in stage IIB cervical carcinoma during pregnancy to allow fetal development and prevent disease progression before delivery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Female. Fetal Development / drug effects. Humans. Pregnancy


15. Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer; 2000 Oct 1;89(7):1440-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, there are grounds for claiming that GSH plays a crucial role in cell proliferation and tumor resistance.
  • In the current study, we investigated the relation between cell growth and GSH levels in the pancreatic adenocarcinoma cell line, AsPC-1, and the significance of GSH in tumor resistance to chemotherapy.
  • METHODS: Cell growth in AsPC-1 was initiated through transforming growth factor-alpha (TGF-alpha) or fetal calf serum (FCS).
  • Then, cell cycle, cell proliferation, and cellular GSH content were analyzed at different times in the presence or absence of buthionine sulfoximine (BSO).
  • The impact of GSH on chemotherapy-induced apoptosis was studied using 5-fluorouracil or melphalan in the presence or absence of BSO.
  • Finally, we compared the GSH content of 15 pancreatic tumor specimens with 10 normal pancreatic tissue specimens.
  • RESULTS: Analysis of GSH in pancreatic tissues demonstrated increased GSH levels in cancerous compared with normal tissue (17.5 +/- 2.3 vs. 8.
  • In addition, GSH-depletion resulted in an increased rate of apoptosis after melphalan (6.3 +/- 0.3 % vs. 11.2 +/- 0.3 %; P < 0.001), but not after 5-fluorouracil treatment.
  • Therefore, GSH-depletion may improve the efficacy of adjuvant therapy in pancreatic carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / pharmacology. Cell Division / physiology. Drug Resistance, Neoplasm. Female. Fluorouracil / pharmacology. Humans. Male. Melphalan / pharmacology. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11013356.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; GAN16C9B8O / Glutathione; Q41OR9510P / Melphalan; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Sharma JB, Gupta P, Kumar S, Roy KK, Malhotra N, Chattopadhyay TK: Esophageal carcinoma during pregnancy: a case report. Arch Gynecol Obstet; 2009 Mar;279(3):401-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hence, the cancer stage is usually advanced at the time of diagnosis.
  • The approach to cancer surgery and chemotherapy must be modified in pregnant patients to minimize fetal and maternal risks.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Female. Humans. Infant, Newborn. Liver Neoplasms / secondary. Male. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629530.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Gourley C, Monaghan H, Beattie G, Court S, Love C, Gabra H: Intra-uterine death resulting from placental metastases in adenocarcinoma of unknown primary. Clin Oncol (R Coll Radiol); 2002 Jun;14(3):213-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-uterine death resulting from placental metastases in adenocarcinoma of unknown primary.
  • Lymph node excision revealed metastatic poorly differentiated adenocarcinoma of unknown primary.
  • The lymph node and cutaneous metastases progressed rapidly so it was decided to initiate systemic chemotherapy with a view to delivery at 28 weeks gestation by Caesarean section.
  • Shortly after the second 3-weekly cycle of cisplatinum chemotherapy the patient suffered severe lower back and hip pain with MRI scan showing multiple bony metastases in the pelvic girdle.
  • As a cause of fetal death, placental metastases are extremely rare.
  • [MeSH-major] Adenocarcinoma / secondary. Fetal Death / etiology. Neoplasms, Unknown Primary. Placenta Diseases / complications. Pregnancy Complications, Neoplastic

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12109824.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Peiretti M, Zakashansky K, Melis GB, Mais V: Unusual case of adenocarcinoma arising in endometriosis mimicking colorectal cancer in a young woman with a Müllerian anomaly. Fertil Steril; 2008 Jul;90(1):199.e13-5
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case of adenocarcinoma arising in endometriosis mimicking colorectal cancer in a young woman with a Müllerian anomaly.
  • OBJECTIVE: To report a case of endometrioid adenocarcinoma that arose in endometriosis mimicking colorectal cancer in a young woman with a Müllerian anomaly.
  • PATIENT(S): A 31-year-old, white nulligravida woman with a history of two previous laparoscopies for infertility and chronic pelvic pain.
  • INTERVENTION(S): The patient was subjected to an exploratory laparotomy followed by adjuvant chemotherapy.
  • CONCLUSION(S): Although a rare event, this condition should be considered in the diagnosis of women with a previous history of pelvic endometriosis, Müllerian malformation, abdominal pain, constipation, or rectal bleeding.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Hysterectomy. Ileostomy. Laparoscopy. Lymph Node Excision. Ovariectomy. Pelvic Pain / etiology. Treatment Outcome


19. Dishop MK, McKay EM, Kreiger PA, Priest JR, Williams GM, Langston C, Jarzembowski J, Suchi M, Dehner LP, Hill DA: Fetal lung interstitial tumor (FLIT): A proposed newly recognized lung tumor of infancy to be differentiated from cystic pleuropulmonary blastoma and other developmental pulmonary lesions. Am J Surg Pathol; 2010 Dec;34(12):1762-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal lung interstitial tumor (FLIT): A proposed newly recognized lung tumor of infancy to be differentiated from cystic pleuropulmonary blastoma and other developmental pulmonary lesions.
  • The differential diagnosis of congenital lung lesions includes a variety of pulmonary malformations, and uncommon or rare neoplasms such as the pleuropulmonary blastoma (PPB) and congenital peribronchial myofibroblastic tumor (CPMT).
  • Although most of the congenital lesions have a predominantly cystic appearance, the exceptions of a more solid process are the type 3 congenital cystic adenomatoid or pulmonary airway malformation (CCAM-CPAM) and the CPMT.
  • The clinical and pathologic features of a unique solid or mixed solid/cystic lung mass composed of immature interstitial mesenchyme in association with irregular airspace-like structures mimicking abnormal incompletely developed lung are presented in this report of 10 infants (7 males, 3 females) whose tumor-like lesions were detected in the prenatal period to 3 months of age (median, 1-day old).
  • A lobectomy was done in all 10 infants and 1 infant received adjuvant chemotherapy.
  • One of the surgical resections occurred as an ex utero, antenatal procedure because of fetal ascites.
  • Because of the morphologic resemblance of this mass-like lesion to fetal lung at 20 to 24 weeks gestation (as though any further pulmonary development was arrested in these localized lesions), we are proposing the designation of fetal lung interstitial tumor (FLIT) whose pathogenetic relationship, if any, to type 1 (cystic) pleuropulmonary blastoma remains uncertain to date.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pulmonary Blastoma / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Cystic Adenomatoid Malformation of Lung, Congenital / diagnosis. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Prenatal Diagnosis

  • Genetic Alliance. consumer health - Pleuropulmonary blastoma.
  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Jul;35(7):1085; author reply 1086-7 [21677544.001]
  • (PMID = 21107081.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Wax JR, Pinette MG, Blackstone J, Cartin A, McCrann DJ: Nonbilharzial bladder carcinoma complicating pregnancy: review of the literature. Obstet Gynecol Surv; 2002 Apr;57(4):236-44
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this review is to evaluate tumor presentation and characteristics, and maternal-fetal outcomes of pregnancies complicated by nonbilharzial bladder carcinoma.
  • Transitional cell carcinoma was found in 17 (74%), adenocarcinoma in 5 (22%), and squamous cell carcinoma in 1 (4.5%) patient.
  • Treatment was typically by transurethral resection (N = 18), but 3 women required radical cystectomy, 2 received radiation, 1 received chemotherapy, and 1 underwent partial cystectomy.
  • Three (14%) women died of their disease and 3 (14%) fetuses were lost because of complications of cancer or its treatment.
  • LEARNING OBJECTIVES: After completion of this article, the reader will be able to list the various types of bladder cancers, to describe the presenting symptoms in a patient with a bladder cancer, and to outline the work up and treatment strategies for bladder cancer.
  • [MeSH-minor] Combined Modality Therapy. Female. Hematuria. Humans. Male. Neoplasm Staging. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11961481.001).
  • [ISSN] 0029-7828
  • [Journal-full-title] Obstetrical & gynecological survey
  • [ISO-abbreviation] Obstet Gynecol Surv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


21. Thelmo MC, Shen EP, Shertukde S: Metastatic pulmonary adenocarcinoma to placenta and pleural fluid: clinicopathologic findings. Fetal Pediatr Pathol; 2010;29(1):45-56
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic pulmonary adenocarcinoma to placenta and pleural fluid: clinicopathologic findings.
  • OBJECTIVES: To report the clinicopathologic findings of a pregnant woman with Stage IV adenocarcinoma of the lung with placental metastasis.
  • RESULTS: A 31-year-old G(2)P(1001) woman was diagnosed with Stage IV metastatic adenocarcinoma of the lung.
  • Placental pathology was significant for adenocarcinoma with a solid and acinar pattern, consistent with that from the lung.
  • She did not receive chemotherapy and expired one month postpartum.
  • CONCLUSIONS: The occurance of lung cancer in pregnancy is rare and a few cases have been reported in literature.
  • Placental metastasis is extremely uncommon in these cases and can lead to fetal involvement by lung tumor.
  • It is important to report all cases of lung cancer occurring in pregnancy with subsequent close clinical surveillance of the infant as all cases have a different clinical picture.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Placenta Diseases / pathology. Pleural Effusion, Malignant / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055563.001).
  • [ISSN] 1551-3823
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Provost PR, Lima PH, Tremblay Y, Blomquist CH: A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer. J Steroid Biochem Mol Biol; 2010 Oct;122(4):295-301
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer.
  • 17β-Hydroxysteroid dehydrogenase/17-ketosteroid reductase (17HSD/KSR) activity and 17HSD/KSR types 1, 2, 4, and 5 mRNA levels were characterized in ovarian cancer cell lines derived from patients unexposed to radiation or chemotherapy.
  • Activity was at the limit of detection in TOV-112D and TOV-21G cells.
  • Activity in OV-90 was comparable to that in human placental tissue, was predominantly microsomal and was 17HSD/KSR type 2-like in substrate specificity and inhibition patterns.
  • In monolayers, conversion of testosterone (T) to androstenedione (A) was 12-fold greater than that of A to T.
  • Reduction of fetal bovine serum to 0.3% in the culture medium had no effect on 17β-HSD activity.
  • Significant levels of type 1 and type 2 mRNAs were observed in OV-90 while only trace amounts were detected in TOV-21G.
  • In contrast, type 4 mRNA levels were comparable for OV-90 and TOV-21G.
  • Type 5 mRNA was detected in both cell lines but its level in OV-90 was twice that of TOV-21G.
  • In OV-90, the type 2-like activity was predominant even though the type 5 mRNA level was 2.5-fold higher than that of the type 2.
  • OV-90 cells may be a useful system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer.
  • [MeSH-major] 17-Hydroxysteroid Dehydrogenases / genetics. 17-Hydroxysteroid Dehydrogenases / metabolism. Adenocarcinoma / enzymology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Epithelial Cells / enzymology. Epithelial Cells / pathology. Female. Humans. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20600897.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.1.1.51 / 3 (or 17)-beta-hydroxysteroid dehydrogenase
  •  go-up   go-down


23. Arck PC, Hertwig K, Hagen E, Hildebrandt M, Klapp BF: Pregnancy as a model of controlled invasion might be attributed to the ratio of CD3/CD8 to CD56. Am J Reprod Immunol; 2000 Jul;44(1):1-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROBLEM: Pregnancy can be considered as a model of successfully controlled tissue invasion.
  • Cellular mediated immunity appears to regulate the controlled invasion of fetal trophoblast cells.
  • METHOD OF STUDY: Decidual tissue from first trimester normal pregnancies (NP; n = 15) and abortion (AB; n = 12), endometrial samples from premenopausal women (NE; n = 8), and endometrioid adenocarcinoma (EA; n = 8) were examined by immunohistochemistry using monoclonal antibody against large spectrum cytokeratin, and against the receptors CD3, CD8, CD56 and CD68, respectively.
  • The decrease of CD56 positive cells in endometrioid adenocarcinoma was statistically significant.
  • [MeSH-minor] Abortion, Induced. Abortion, Spontaneous / immunology. Adenocarcinoma / immunology. Adult. Antigens, CD3 / analysis. Antigens, CD56 / analysis. Antigens, CD8 / analysis. Decidua / cytology. Decidua / immunology. Endometrial Neoplasms / immunology. Endometrium / immunology. Female. Humans. Immunohistochemistry. Lymphocyte Count. Middle Aged. Pregnancy Trimester, First / immunology. Premenopause / immunology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976806.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD56; 0 / Antigens, CD8
  •  go-up   go-down


24. Reinblatt M, Pin RH, Bowers WJ, Federoff HJ, Fong Y: Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann Surg Oncol; 2005 Dec;12(12):1025-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma.
  • BACKGROUND: Tumor hypoxia induces vascular endothelial growth factor (VEGF) expression, which stimulates angiogenesis and tumor proliferation.
  • The VEGF signaling pathway is inhibited by soluble VEGF receptors (soluble fetal liver kinase 1; sFlk-1), which bind VEGF and block its interaction with endothelial cells.
  • We attempted to attenuate angiogenesis and inhibit pancreatic tumor growth through HSV amplicon-mediated expression of sFlk-1 under hypoxic control.
  • A novel HSV amplicon expressing 10 x HRE/sFlk-1 was genetically engineered (HSV10 x HRE/sFlk-1).Human pancreatic adenocarcinoma cells (AsPC1) were transduced with HSV10 x HRE/sFlk-1 and incubated in normoxia (21% oxygen) or hypoxia (1% oxygen).
  • AsPC1 flank tumor xenografts (n = 24) were transduced with HSV10 x HRE/sFlk-1.
  • CONCLUSIONS: HSV amplicon delivery of a hypoxia-inducible soluble VEGF receptor significantly reduces new vessel formation and tumor growth.
  • Tumor hypoxia can thus be used to direct antiangiogenic therapy to pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / administration & dosage. Hypoxia-Inducible Factor 1. Neovascularization, Physiologic / drug effects. Pancreatic Neoplasms / therapy. Vascular Endothelial Growth Factor Receptor-2 / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244806.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 76416; United States / NCI NIH HHS / CA / R01 CA/DK 80982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Hypoxia-Inducible Factor 1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


25. Sodano M, Bogliatto F, Morero S, Mosso L, Torchio B, Leidi L: Case report: Successful IVF programme after conservatively treated endometrial cancer. Reprod Biomed Online; 2009 Apr;18(4):578-81
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper presents such a case, an infertile patient with conservatively treated endometrial cancer (stage 1a grade 1) who conceived and carried a successful pregnancy after IVF treatment.
  • The conservative treatment consisted of hysteroscopic biopsies and oral megestrol acetate 600 mg daily for 3 months.
  • At the end of the treatment the endometrial cancer remitted to simple endometrial hyperplasia.
  • IVF was performed immediately and 32 days after embryo transfer an intrauterine single gestational sac with fetal pole and heartbeat was detected by transvaginal ultrasound.
  • It is concluded that conservative treatment of stage 1a and grade 1 endometrial adenocarcinoma is an available option in young women who wish to preserve their fertility.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Embryo Transfer / methods. Endometrial Neoplasms / drug therapy. Fertilization in Vitro / methods. Megestrol Acetate / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Pregnancy. Pregnancy Outcome. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401002.001).
  • [ISSN] 1472-6491
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


26. Tang XJ, Wang YP, Zhou QH, Che GW, Chen XH, Zhu DX: [A study on selective killing effect of Hsv-tk/GCV driven by human telomerase catalytic subunit promoter on human lung cancer cell A549]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Apr;24(2):148-52
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A study on selective killing effect of Hsv-tk/GCV driven by human telomerase catalytic subunit promoter on human lung cancer cell A549].
  • OBJECTIVE: To study selective killing effect of herpes simplex virus-thymidine kinase/ganciclovir (Hsv-tk/GCV) driven by human telomerase catalytic subunit (hTERT) promoter on lung cancer cell line A549 in vitro. METHODS:.
  • (1) Expression plasmids of Hsv-tk gene driven by hTERT promoter and sv40 promoter respectively (pGL3-hTp-tk and pGL3-sv40-tk) were transfected into telomerase-positive human lung adenocarcinoma cell line A549 and telomerase-negative fetal lung fibroblast cell line MRC-5.
  • (3) Treated with GCV, apoptosis index (AI) of pGL3-sv40-tk transfected A549 and MRC-5 as well as pGL3-hTp-tk transfected A549 (21.58%, 9.35% and 23.19% respectively) increased significantly, compared with A549, MRC-5 transfected with pGL3-hTp (0.78% and 0.55% respectively) and A549, MRC-5 without plasmid transfection as blank control (2.17% and 0.60% respectively); GCV had no influence on AI of pGL3-hTp-tk transfected MRC-5 (0.88%).
  • CONCLUSION: tk gene driven by hTERT promoter could express selectively in lung cancer cell A549.
  • Hsv-tk/GCV driven by hTERT promoter could selectively inhibit proliferation of lung cancer cell.
  • [MeSH-minor] Antiviral Agents / pharmacology. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Genetic Therapy / methods. Humans. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Reverse Transcriptase Polymerase Chain Reaction. Simplexvirus / enzymology. Simplexvirus / genetics. Transfection. Viral Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17407070.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Viral Proteins; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.7.49 / Telomerase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


27. Andrijevic Lj, Radotic K, Bogdanovic J, Mutavdzic D, Bogdanovic G: Antiproliferative effect of synthetic lignin against human breast cancer and normal fetal lung cell lines. Potency of low molecular weight fractions. J BUON; 2008 Apr-Jun;13(2):241-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effect of synthetic lignin against human breast cancer and normal fetal lung cell lines. Potency of low molecular weight fractions.
  • PURPOSE: Due to a lack of chemotherapeutics to efficiently control neoplastic processes, there is a need for discovering new, more efficient anticancer drugs that would distinguish malignant from normal cells.
  • MATERIALS AND METHODS: We studied the effect of short (4 h) and long (72 h) treatment with different concentrations of the enzymatically synthesized lignin model compound (DHP) on the proliferation of two human cell lines grown in tissue culture: breast adenocarcinoma (MCF7) and normal fetal lung fibroblast (MRC5) cell lines.
  • RESULTS: The growth of both MRC5 and MCF7 cell lines was inhibited by DHP after 4 h-treatment, while the carcinoma cell line was also sensitive to the long-term treatment with lower dose of DHP in comparison with the fetal cells.
  • The low molecular weight DHP fractions inhibited growth of the MRC5 cells at lower concentrations compared to the treatment with all DHP fractions.
  • CONCLUSION: The higher sensitivity to DHP of the human malignant cells compared to the normal transformed ones gives the possibility to further study DHP as a therapeutic agent.
  • [MeSH-major] Breast Neoplasms / drug therapy. Cell Proliferation / drug effects. Fibroblasts / drug effects. Lignin / therapeutic use. Lung / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Cells, Cultured. Fetus / drug effects. Humans. Molecular Weight

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555472.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 9005-53-2 / Lignin
  •  go-up   go-down


28. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS: The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol; 2002 Oct;128(10):525-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arachidonic acid (AA)-metabolizing enzymes have been implicated in aggressive clinical behavior of pancreatic cancer while mutations in the Ki- ras gene have been associated with prolonged survival and responsiveness to therapy.
  • Starting at 4 weeks of age, groups of offspring were given either the COX inhibitor ibuprofen (infant Motrin oral suspension) or the FLAP-inhibitor MK886 (dissolved in carboxymethylcellulose orally) for life while a group of offspring not receiving any treatment served as positive controls.
  • CONCLUSION: In conjunction with the documented over-expression of COX-2 and LOX in human pancreatic cancer, our findings suggest an important role of the AA-cascade in the genesis of this cancer type and indicate that pharmacological or dietary measures that reduce AA-metabolism may be useful for the prevention and clinical management of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / prevention & control. Cyclooxygenase Inhibitors / therapeutic use. Ibuprofen / therapeutic use. Indoles / therapeutic use. Lipoxygenase Inhibitors / therapeutic use. Pancreatic Neoplasms / prevention & control
  • [MeSH-minor] Animals. Arachidonic Acid / metabolism. Cricetinae. DNA Primers / chemistry. Ethanol / toxicity. Female. Genes, p53 / genetics. Genes, ras / genetics. Male. Maternal-Fetal Exchange / drug effects. Mesocricetus. Nitrosamines / toxicity. Pancreas / drug effects. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Pregnancy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12384795.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA42829
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / DNA Primers; 0 / Indoles; 0 / Lipoxygenase Inhibitors; 0 / Nitrosamines; 118414-82-7 / L 663536; 27YG812J1I / Arachidonic Acid; 3K9958V90M / Ethanol; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


29. Leung WN, Sun X, Mak NK, Yow CM: Photodynamic effects of mTHPC on human colon adenocarcinoma cells: photocytotoxicity, subcellular localization and apoptosis. Photochem Photobiol; 2002 Apr;75(4):406-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic effects of mTHPC on human colon adenocarcinoma cells: photocytotoxicity, subcellular localization and apoptosis.
  • The photodynamic properties of meta-tetra(hydroxyphenyl)chlorin (mTHPC), a promising second-generation photosensitizer, were investigated using a human colon adenocarcinoma cell line (Colo 201 cells).
  • The photocytotoxicity of mTHPC showed both drug and light dose-dependent characteristics.
  • The presence of 10% fetal calf serum in culture medium significantly decreased the incorporation of mTHPC into cells and resulted in the reduction of photodynamic efficacy.
  • Furthermore, nuclear stainings demonstrated that photodynamic therapy with mTHPC induced apoptosis in Colo 201 cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Apoptosis / drug effects. Colonic Neoplasms / drug therapy. Mesoporphyrins / pharmacology. Photochemotherapy. Photosensitizing Agents / pharmacology. Subcellular Fractions / metabolism
  • [MeSH-minor] Humans. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12003131.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


30. Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA: Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate; 2008 Jul 1;68(10):1133-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Androgen deprivation is the only effective systemic therapy available for patients with prostatic carcinoma, but is associated with a gradual transition to a hormone-refractory prostate cancer (HRCAP) in which ligand-independent activation of the androgen receptor has been implicated.
  • The beta(2)-adrenergic receptor (beta(2)-AR) is a well-known activator of the androgen receptor.
  • METHODS: Prostatic cell lines were analyzed using cDNA micro-array, real time RT-PCR, radioligand binding assay, cAMP measurements, transfection and thymidine incorporation assay.
  • RESULTS: Here, we show that beta(2)-AR was transiently down-regulated both at mRNA- and protein levels when hormone-sensitive prostate cancer cells, LNCaP, were cultured in steroid stripped medium (charcoal-stripped fetal calf serum) or when the cells were treated with the anti-androgen, bicalutamide (Casodex).
  • Immunohistochemical staining of human prostate specimens showed high expression of beta(2)-AR in glandular, epithelial cells and increased expression in malignant cells compared to benign hyperplasia and normal tissue.
  • Interestingly, beta(2)-AR mRNA was strongly down-regulated by androgen ablation therapy of prostate cancer patients.
  • CONCLUSION: The level of beta(2)-AR was increased by T3 in prostatic adenocarcinoma cells and reduced in prostate cancer patients who had received androgen ablation therapy for 3 months.
  • [MeSH-major] Adenocarcinoma / physiopathology. Prostatic Neoplasms / physiopathology. Receptors, Adrenergic, beta-2 / genetics. Receptors, Adrenergic, beta-2 / metabolism
  • [MeSH-minor] Androgen Antagonists / pharmacology. Androgen Antagonists / therapeutic use. Androgens / metabolism. Anilides / pharmacology. Antineoplastic Agents / pharmacology. Biopsy. Cell Line, Tumor. Down-Regulation. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / physiology. Humans. Immunohistochemistry. Male. Nitriles / pharmacology. Oligonucleotide Array Sequence Analysis. Prostate / metabolism. Prostate / pathology. Receptors, Androgen / metabolism. Signal Transduction / drug effects. Signal Transduction / physiology. Tosyl Compounds / pharmacology. Triiodothyronine / pharmacology. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18454446.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Anilides; 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Receptors, Adrenergic, beta-2; 0 / Receptors, Androgen; 0 / Tosyl Compounds; 06LU7C9H1V / Triiodothyronine; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down






Advertisement